| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 92 | 2025 | 5097 | 6.650 |
Why?
|
| Condoms, Female | 27 | 2022 | 41 | 6.440 |
Why?
|
| Sexual Partners | 38 | 2025 | 215 | 4.930 |
Why?
|
| Sexual Behavior | 35 | 2024 | 320 | 4.670 |
Why?
|
| Health Knowledge, Attitudes, Practice | 28 | 2024 | 262 | 4.360 |
Why?
|
| Contraception | 24 | 2024 | 90 | 4.080 |
Why?
|
| Pre-Exposure Prophylaxis | 19 | 2025 | 196 | 3.960 |
Why?
|
| Family Planning Services | 12 | 2023 | 46 | 3.940 |
Why?
|
| Female | 162 | 2025 | 9103 | 3.860 |
Why?
|
| South Africa | 122 | 2025 | 7596 | 3.390 |
Why?
|
| Humans | 187 | 2025 | 14537 | 3.360 |
Why?
|
| Adult | 109 | 2025 | 5913 | 3.120 |
Why?
|
| Health Personnel | 14 | 2023 | 231 | 3.050 |
Why?
|
| Contraception Behavior | 16 | 2023 | 54 | 3.030 |
Why?
|
| Condoms | 16 | 2024 | 88 | 3.030 |
Why?
|
| Sexually Transmitted Diseases | 23 | 2025 | 103 | 3.020 |
Why?
|
| Reproductive Health Services | 14 | 2024 | 66 | 2.970 |
Why?
|
| Pregnancy Complications, Infectious | 14 | 2025 | 529 | 2.890 |
Why?
|
| Contraceptive Agents, Female | 13 | 2024 | 47 | 2.840 |
Why?
|
| Adolescent | 80 | 2025 | 2985 | 2.770 |
Why?
|
| Young Adult | 73 | 2025 | 2498 | 2.740 |
Why?
|
| Patient Acceptance of Health Care | 20 | 2024 | 256 | 2.590 |
Why?
|
| Pregnancy | 49 | 2025 | 1862 | 2.530 |
Why?
|
| Tenofovir | 6 | 2025 | 171 | 2.530 |
Why?
|
| Anti-HIV Agents | 17 | 2025 | 1324 | 2.520 |
Why?
|
| Medication Adherence | 8 | 2025 | 151 | 2.290 |
Why?
|
| Male | 78 | 2025 | 6754 | 2.220 |
Why?
|
| Fertilization | 8 | 2024 | 22 | 2.050 |
Why?
|
| Students | 4 | 2020 | 50 | 1.920 |
Why?
|
| Safe Sex | 18 | 2024 | 68 | 1.920 |
Why?
|
| Risk-Taking | 14 | 2020 | 121 | 1.860 |
Why?
|
| Infectious Disease Transmission, Vertical | 7 | 2020 | 472 | 1.810 |
Why?
|
| Reproductive Health | 9 | 2024 | 51 | 1.810 |
Why?
|
| Medroxyprogesterone Acetate | 15 | 2024 | 44 | 1.740 |
Why?
|
| HIV | 6 | 2020 | 380 | 1.700 |
Why?
|
| Public Sector | 5 | 2023 | 82 | 1.650 |
Why?
|
| Community Participation | 4 | 2019 | 42 | 1.420 |
Why?
|
| Counseling | 10 | 2023 | 143 | 1.350 |
Why?
|
| Intrauterine Devices, Copper | 4 | 2024 | 20 | 1.340 |
Why?
|
| Qualitative Research | 17 | 2025 | 321 | 1.340 |
Why?
|
| Chlamydia Infections | 6 | 2023 | 17 | 1.280 |
Why?
|
| Middle Aged | 34 | 2024 | 3601 | 1.220 |
Why?
|
| Focus Groups | 19 | 2024 | 196 | 1.170 |
Why?
|
| Norethindrone | 11 | 2024 | 26 | 1.130 |
Why?
|
| Sex Counseling | 4 | 2016 | 9 | 1.120 |
Why?
|
| Intention | 4 | 2021 | 23 | 1.120 |
Why?
|
| Attitude of Health Personnel | 3 | 2018 | 106 | 1.080 |
Why?
|
| Pregnancy, Unplanned | 5 | 2021 | 19 | 1.070 |
Why?
|
| Gonorrhea | 5 | 2020 | 20 | 1.070 |
Why?
|
| Genitalia, Female | 2 | 2020 | 17 | 1.000 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2018 | 33 | 0.970 |
Why?
|
| Professional-Patient Relations | 2 | 2015 | 14 | 0.930 |
Why?
|
| Postpartum Period | 4 | 2023 | 85 | 0.920 |
Why?
|
| Menstrual Hygiene Products | 3 | 2020 | 8 | 0.920 |
Why?
|
| Cross-Over Studies | 16 | 2022 | 40 | 0.900 |
Why?
|
| Social Support | 4 | 2020 | 77 | 0.900 |
Why?
|
| Interviews as Topic | 15 | 2024 | 203 | 0.900 |
Why?
|
| Health Services Accessibility | 7 | 2024 | 280 | 0.870 |
Why?
|
| Choice Behavior | 4 | 2021 | 16 | 0.850 |
Why?
|
| Hygiene | 3 | 2020 | 23 | 0.840 |
Why?
|
| Men | 3 | 2021 | 15 | 0.830 |
Why?
|
| Universities | 4 | 2020 | 34 | 0.830 |
Why?
|
| Drug Users | 1 | 2023 | 3 | 0.820 |
Why?
|
| Interpersonal Relations | 7 | 2019 | 43 | 0.820 |
Why?
|
| Hepatitis C | 1 | 2023 | 37 | 0.800 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 112 | 0.790 |
Why?
|
| Sex Workers | 7 | 2018 | 116 | 0.790 |
Why?
|
| Surveys and Questionnaires | 13 | 2023 | 563 | 0.740 |
Why?
|
| Consumer Behavior | 5 | 2019 | 20 | 0.730 |
Why?
|
| Social Stigma | 7 | 2024 | 80 | 0.730 |
Why?
|
| Contraceptive Devices, Female | 5 | 2024 | 30 | 0.730 |
Why?
|
| Equipment Failure | 7 | 2019 | 13 | 0.720 |
Why?
|
| HIV Seropositivity | 9 | 2022 | 265 | 0.710 |
Why?
|
| Cross-Sectional Studies | 21 | 2021 | 1422 | 0.700 |
Why?
|
| Patient Satisfaction | 8 | 2022 | 43 | 0.690 |
Why?
|
| Hair Removal | 1 | 2020 | 1 | 0.680 |
Why?
|
| Genitalia, Male | 1 | 2020 | 9 | 0.680 |
Why?
|
| Herpes Genitalis | 1 | 2020 | 43 | 0.660 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2022 | 187 | 0.660 |
Why?
|
| Patient Preference | 5 | 2025 | 30 | 0.650 |
Why?
|
| Circumcision, Male | 4 | 2018 | 99 | 0.650 |
Why?
|
| Kidney Transplantation | 16 | 1996 | 42 | 0.650 |
Why?
|
| Sexual Health | 2 | 2024 | 14 | 0.650 |
Why?
|
| Levonorgestrel | 4 | 2024 | 17 | 0.630 |
Why?
|
| Contraception, Barrier | 2 | 2018 | 5 | 0.620 |
Why?
|
| Adolescent Behavior | 4 | 2014 | 60 | 0.600 |
Why?
|
| Contact Tracing | 3 | 2025 | 48 | 0.590 |
Why?
|
| Sexuality | 4 | 2012 | 11 | 0.590 |
Why?
|
| Mass Screening | 1 | 2020 | 245 | 0.580 |
Why?
|
| Anti-Retroviral Agents | 4 | 2021 | 551 | 0.580 |
Why?
|
| Contraceptive Agents | 5 | 2023 | 27 | 0.570 |
Why?
|
| Health Policy | 4 | 2020 | 140 | 0.540 |
Why?
|
| Incidence | 10 | 2024 | 685 | 0.540 |
Why?
|
| Depression | 5 | 2021 | 121 | 0.540 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 52 | 0.530 |
Why?
|
| Zambia | 5 | 2023 | 115 | 0.520 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 239 | 0.510 |
Why?
|
| Self Administration | 1 | 2016 | 5 | 0.510 |
Why?
|
| Pregnancy in Adolescence | 2 | 2014 | 15 | 0.510 |
Why?
|
| AIDS Serodiagnosis | 1 | 2016 | 44 | 0.490 |
Why?
|
| Prevalence | 10 | 2023 | 1192 | 0.490 |
Why?
|
| Communication Barriers | 2 | 2020 | 10 | 0.490 |
Why?
|
| Administration, Oral | 5 | 2025 | 127 | 0.480 |
Why?
|
| Attitude to Health | 6 | 2014 | 56 | 0.470 |
Why?
|
| Contraceptives, Oral, Combined | 7 | 2011 | 9 | 0.460 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 3 | 2019 | 24 | 0.450 |
Why?
|
| Unsafe Sex | 2 | 2014 | 46 | 0.450 |
Why?
|
| Reproduction | 1 | 2014 | 25 | 0.450 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 370 | 0.430 |
Why?
|
| Chemoprevention | 3 | 2024 | 33 | 0.430 |
Why?
|
| Papio | 17 | 1996 | 28 | 0.410 |
Why?
|
| Drug Substitution | 1 | 2013 | 33 | 0.400 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2024 | 11 | 0.390 |
Why?
|
| Pyrimidines | 2 | 2024 | 32 | 0.380 |
Why?
|
| Sex Education | 4 | 2019 | 17 | 0.380 |
Why?
|
| Longitudinal Studies | 6 | 2025 | 435 | 0.370 |
Why?
|
| Health Services Needs and Demand | 4 | 2019 | 57 | 0.360 |
Why?
|
| Disease Transmission, Infectious | 3 | 2024 | 39 | 0.360 |
Why?
|
| Health Behavior | 3 | 2019 | 79 | 0.350 |
Why?
|
| Prospective Studies | 8 | 2025 | 1160 | 0.330 |
Why?
|
| Animals | 19 | 2020 | 1081 | 0.320 |
Why?
|
| Cohort Studies | 8 | 2025 | 967 | 0.310 |
Why?
|
| Polyurethanes | 2 | 2006 | 3 | 0.310 |
Why?
|
| Latex | 2 | 2006 | 3 | 0.310 |
Why?
|
| Women | 3 | 2017 | 12 | 0.300 |
Why?
|
| Progestins | 2 | 2023 | 14 | 0.300 |
Why?
|
| Program Evaluation | 3 | 2019 | 89 | 0.300 |
Why?
|
| HIV-1 | 5 | 2022 | 1260 | 0.290 |
Why?
|
| Vagina | 4 | 2020 | 91 | 0.290 |
Why?
|
| Contraceptives, Oral, Hormonal | 4 | 2013 | 6 | 0.290 |
Why?
|
| Menstruation | 2 | 2020 | 10 | 0.290 |
Why?
|
| Negotiating | 3 | 2018 | 8 | 0.290 |
Why?
|
| Chlamydia trachomatis | 4 | 2023 | 13 | 0.280 |
Why?
|
| Neisseria gonorrhoeae | 4 | 2023 | 15 | 0.280 |
Why?
|
| Lymphocytes | 7 | 1996 | 20 | 0.270 |
Why?
|
| Aged | 4 | 2020 | 1740 | 0.270 |
Why?
|
| Bone Density | 4 | 2010 | 107 | 0.270 |
Why?
|
| Drug Delivery Systems | 2 | 2019 | 252 | 0.270 |
Why?
|
| Women's Health | 4 | 2011 | 41 | 0.250 |
Why?
|
| Risk Factors | 10 | 2020 | 1475 | 0.240 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 2 | 2020 | 4 | 0.240 |
Why?
|
| Equipment Design | 4 | 2019 | 27 | 0.240 |
Why?
|
| Transplantation, Heterologous | 7 | 1996 | 9 | 0.240 |
Why?
|
| Histocompatibility Testing | 7 | 1994 | 26 | 0.230 |
Why?
|
| Device Removal | 2 | 2024 | 14 | 0.230 |
Why?
|
| Lubrication | 2 | 2020 | 3 | 0.230 |
Why?
|
| Patient Education as Topic | 3 | 2014 | 48 | 0.230 |
Why?
|
| Feasibility Studies | 4 | 2019 | 101 | 0.230 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2024 | 7 | 0.220 |
Why?
|
| Testosterone | 1 | 2024 | 14 | 0.220 |
Why?
|
| Intrauterine Devices | 2 | 2023 | 9 | 0.220 |
Why?
|
| Kenya | 7 | 2020 | 183 | 0.220 |
Why?
|
| Harm Reduction | 1 | 2024 | 7 | 0.220 |
Why?
|
| Plasma | 1 | 2024 | 39 | 0.220 |
Why?
|
| Preventive Health Services | 2 | 2016 | 17 | 0.220 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.220 |
Why?
|
| Immune Tolerance | 5 | 1994 | 22 | 0.210 |
Why?
|
| Trichomonas vaginalis | 1 | 2023 | 5 | 0.210 |
Why?
|
| Pregnant Women | 2 | 2021 | 89 | 0.210 |
Why?
|
| T-Lymphocytes | 7 | 1994 | 65 | 0.210 |
Why?
|
| Contraceptives, Postcoital | 2 | 2004 | 3 | 0.200 |
Why?
|
| Whole-Body Irradiation | 8 | 1996 | 9 | 0.200 |
Why?
|
| Mozambique | 7 | 2017 | 55 | 0.200 |
Why?
|
| Needs Assessment | 3 | 2019 | 29 | 0.200 |
Why?
|
| Hepacivirus | 1 | 2023 | 37 | 0.200 |
Why?
|
| Vaginal Discharge | 1 | 2002 | 3 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 4 | 2023 | 125 | 0.200 |
Why?
|
| Graft Rejection | 6 | 1994 | 15 | 0.190 |
Why?
|
| Socioeconomic Factors | 8 | 2019 | 411 | 0.190 |
Why?
|
| Africa South of the Sahara | 4 | 2018 | 353 | 0.190 |
Why?
|
| Motivation | 4 | 2016 | 59 | 0.190 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2021 | 1 | 0.190 |
Why?
|
| Family Characteristics | 3 | 2021 | 135 | 0.180 |
Why?
|
| Injections, Intramuscular | 4 | 2024 | 31 | 0.180 |
Why?
|
| Quality of Health Care | 1 | 2021 | 62 | 0.180 |
Why?
|
| Disclosure | 1 | 2021 | 25 | 0.180 |
Why?
|
| Fertility | 1 | 2021 | 22 | 0.180 |
Why?
|
| Income | 1 | 2021 | 85 | 0.180 |
Why?
|
| Desogestrel | 1 | 2021 | 2 | 0.180 |
Why?
|
| Graft Survival | 9 | 1994 | 40 | 0.180 |
Why?
|
| Cell Phone Use | 1 | 2021 | 6 | 0.170 |
Why?
|
| Risk Reduction Behavior | 2 | 2018 | 39 | 0.170 |
Why?
|
| Silicones | 1 | 2020 | 2 | 0.170 |
Why?
|
| Vaginal Douching | 2 | 2011 | 8 | 0.170 |
Why?
|
| Lacerations | 1 | 2020 | 1 | 0.170 |
Why?
|
| Retreatment | 1 | 2020 | 6 | 0.170 |
Why?
|
| Intimate Partner Violence | 2 | 2019 | 55 | 0.170 |
Why?
|
| Health Promotion | 4 | 2015 | 109 | 0.170 |
Why?
|
| Herpesvirus 2, Human | 1 | 2020 | 43 | 0.170 |
Why?
|
| Self Report | 2 | 2024 | 114 | 0.170 |
Why?
|
| Heroin Dependence | 1 | 2020 | 8 | 0.170 |
Why?
|
| Alcoholism | 1 | 2020 | 17 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2021 | 111 | 0.160 |
Why?
|
| Private Sector | 1 | 2020 | 45 | 0.160 |
Why?
|
| Interleukin-2 | 6 | 1996 | 22 | 0.160 |
Why?
|
| National Health Programs | 1 | 2020 | 78 | 0.160 |
Why?
|
| Child | 5 | 2021 | 2242 | 0.160 |
Why?
|
| Follicle Stimulating Hormone | 3 | 2011 | 11 | 0.160 |
Why?
|
| Breast Feeding | 1 | 2020 | 120 | 0.150 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 468 | 0.150 |
Why?
|
| Reproductive Tract Infections | 1 | 2018 | 8 | 0.150 |
Why?
|
| Women's Health Services | 2 | 2018 | 12 | 0.150 |
Why?
|
| Quinine | 1 | 1998 | 3 | 0.150 |
Why?
|
| Abortifacient Agents | 1 | 1998 | 4 | 0.150 |
Why?
|
| Zimbabwe | 4 | 2021 | 120 | 0.140 |
Why?
|
| Community Health Centers | 1 | 2018 | 9 | 0.140 |
Why?
|
| Truth Disclosure | 1 | 2018 | 18 | 0.140 |
Why?
|
| Family Relations | 1 | 2018 | 7 | 0.140 |
Why?
|
| Diaphragm | 1 | 2018 | 2 | 0.140 |
Why?
|
| Decision Making | 3 | 2013 | 53 | 0.140 |
Why?
|
| Self Efficacy | 1 | 2018 | 11 | 0.140 |
Why?
|
| Uganda | 4 | 2024 | 197 | 0.140 |
Why?
|
| Administration, Intravaginal | 4 | 2021 | 50 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 43 | 0.140 |
Why?
|
| Health Risk Behaviors | 1 | 2017 | 7 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 293 | 0.140 |
Why?
|
| Prenatal Care | 1 | 2019 | 147 | 0.140 |
Why?
|
| Menopause | 2 | 2011 | 24 | 0.140 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 57 | 0.140 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 20 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2015 | 120 | 0.140 |
Why?
|
| Lymphatic System | 4 | 1989 | 4 | 0.130 |
Why?
|
| Urban Population | 3 | 2021 | 257 | 0.130 |
Why?
|
| Cultural Characteristics | 6 | 2013 | 15 | 0.130 |
Why?
|
| Home Nursing | 1 | 2016 | 8 | 0.130 |
Why?
|
| Lymphocyte Culture Test, Mixed | 6 | 1994 | 7 | 0.130 |
Why?
|
| Lymphokines | 1 | 1996 | 1 | 0.130 |
Why?
|
| Th2 Cells | 1 | 1996 | 2 | 0.130 |
Why?
|
| Th1 Cells | 1 | 1996 | 6 | 0.130 |
Why?
|
| Health Education | 1 | 2016 | 35 | 0.120 |
Why?
|
| Injections | 2 | 2013 | 31 | 0.120 |
Why?
|
| Nurse Administrators | 1 | 2015 | 9 | 0.120 |
Why?
|
| Rural Population | 3 | 2012 | 654 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 472 | 0.120 |
Why?
|
| Nurses | 1 | 2015 | 32 | 0.120 |
Why?
|
| Absorbent Pads | 1 | 2015 | 2 | 0.120 |
Why?
|
| Lymphoid Tissue | 6 | 1994 | 7 | 0.120 |
Why?
|
| Receptors, Interleukin-2 | 3 | 1992 | 5 | 0.120 |
Why?
|
| India | 4 | 2017 | 62 | 0.120 |
Why?
|
| Logistic Models | 4 | 2021 | 254 | 0.110 |
Why?
|
| Dancing | 1 | 2014 | 1 | 0.110 |
Why?
|
| Endemic Diseases | 1 | 2014 | 15 | 0.110 |
Why?
|
| Time Factors | 6 | 2007 | 507 | 0.110 |
Why?
|
| Preconception Care | 2 | 2024 | 12 | 0.110 |
Why?
|
| DNA Repair | 1 | 1994 | 11 | 0.110 |
Why?
|
| DNA Damage | 1 | 1994 | 12 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 51 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 1994 | 62 | 0.100 |
Why?
|
| Vaginal Diseases | 2 | 2011 | 4 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2020 | 225 | 0.100 |
Why?
|
| Delayed-Action Preparations | 4 | 2020 | 68 | 0.100 |
Why?
|
| Drug Implants | 2 | 2024 | 24 | 0.100 |
Why?
|
| Cells, Cultured | 5 | 1996 | 79 | 0.100 |
Why?
|
| Peer Group | 1 | 2012 | 14 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2020 | 889 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2011 | 240 | 0.090 |
Why?
|
| Pregnancy, Unwanted | 4 | 2016 | 9 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 244 | 0.090 |
Why?
|
| Africa | 2 | 2025 | 376 | 0.090 |
Why?
|
| Ceremonial Behavior | 1 | 2011 | 2 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 1991 | 2 | 0.090 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1991 | 5 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 45 | 0.090 |
Why?
|
| United States | 3 | 2020 | 132 | 0.080 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 31 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 1994 | 231 | 0.080 |
Why?
|
| Reproductive Rights | 1 | 2009 | 5 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 1 | 2009 | 16 | 0.080 |
Why?
|
| Withholding Treatment | 1 | 2010 | 26 | 0.080 |
Why?
|
| Data Collection | 1 | 2010 | 86 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2023 | 321 | 0.080 |
Why?
|
| Weight Gain | 1 | 2010 | 77 | 0.080 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 1989 | 1 | 0.080 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2009 | 11 | 0.080 |
Why?
|
| Coitus | 2 | 2019 | 15 | 0.080 |
Why?
|
| Antibody Formation | 1 | 1989 | 61 | 0.080 |
Why?
|
| Age Factors | 4 | 2020 | 370 | 0.070 |
Why?
|
| Contraception, Postcoital | 1 | 2007 | 1 | 0.070 |
Why?
|
| Cities | 2 | 2018 | 37 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2007 | 11 | 0.070 |
Why?
|
| Tacrolimus | 2 | 1996 | 5 | 0.060 |
Why?
|
| Organophosphates | 1 | 2025 | 9 | 0.060 |
Why?
|
| Contraceptive Devices | 2 | 2021 | 3 | 0.060 |
Why?
|
| Needle-Exchange Programs | 1 | 2024 | 3 | 0.060 |
Why?
|
| Adenine | 1 | 2025 | 91 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 1994 | 40 | 0.060 |
Why?
|
| Estradiol | 1 | 2024 | 18 | 0.050 |
Why?
|
| Policy Making | 2 | 2016 | 32 | 0.050 |
Why?
|
| Urban Health | 3 | 2012 | 78 | 0.050 |
Why?
|
| Sex Factors | 2 | 2019 | 227 | 0.050 |
Why?
|
| Materials Testing | 2 | 2014 | 16 | 0.050 |
Why?
|
| Biomarkers | 3 | 2003 | 327 | 0.050 |
Why?
|
| China | 2 | 2013 | 21 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 30 | 0.050 |
Why?
|
| Parenting | 1 | 2023 | 22 | 0.050 |
Why?
|
| Amenorrhea | 1 | 2002 | 9 | 0.050 |
Why?
|
| Primary Prevention | 2 | 2013 | 27 | 0.050 |
Why?
|
| Lymphocyte Transfusion | 2 | 1996 | 2 | 0.050 |
Why?
|
| Infant | 2 | 2023 | 2244 | 0.050 |
Why?
|
| Health Status | 1 | 2023 | 111 | 0.050 |
Why?
|
| Global Health | 3 | 2008 | 193 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 118 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 101 | 0.050 |
Why?
|
| Research Design | 2 | 2012 | 124 | 0.040 |
Why?
|
| Cadaver | 3 | 1991 | 5 | 0.040 |
Why?
|
| Educational Status | 3 | 2007 | 68 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 306 | 0.040 |
Why?
|
| Indonesia | 2 | 2011 | 7 | 0.040 |
Why?
|
| Thailand | 2 | 2011 | 26 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 46 | 0.040 |
Why?
|
| Genotype | 1 | 2022 | 442 | 0.040 |
Why?
|
| Prognosis | 2 | 1991 | 199 | 0.040 |
Why?
|
| Heroin | 1 | 2020 | 4 | 0.040 |
Why?
|
| Obesity | 1 | 2023 | 367 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 35 | 0.040 |
Why?
|
| Gender Identity | 2 | 2011 | 23 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2022 | 278 | 0.040 |
Why?
|
| Culture | 2 | 2011 | 23 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2019 | 11 | 0.040 |
Why?
|
| Immunosuppressive Agents | 3 | 1996 | 20 | 0.040 |
Why?
|
| Psychometrics | 1 | 2019 | 22 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 179 | 0.040 |
Why?
|
| Trichomonas Vaginitis | 1 | 2018 | 4 | 0.040 |
Why?
|
| Trichomonas Infections | 1 | 2018 | 5 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2018 | 7 | 0.040 |
Why?
|
| Syphilis | 1 | 2018 | 14 | 0.040 |
Why?
|
| Vaginosis, Bacterial | 1 | 2018 | 19 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1996 | 7 | 0.040 |
Why?
|
| Candidiasis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Africa, Southern | 1 | 2018 | 91 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 125 | 0.040 |
Why?
|
| Heterosexuality | 1 | 2018 | 30 | 0.040 |
Why?
|
| Physicians | 1 | 2018 | 31 | 0.040 |
Why?
|
| Cell Separation | 2 | 1988 | 6 | 0.040 |
Why?
|
| Health Surveys | 2 | 2011 | 59 | 0.040 |
Why?
|
| Spouse Abuse | 1 | 2017 | 12 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 171 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2003 | 188 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2011 | 799 | 0.030 |
Why?
|
| Community Health Workers | 1 | 2018 | 66 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2017 | 23 | 0.030 |
Why?
|
| Financing, Personal | 1 | 2017 | 12 | 0.030 |
Why?
|
| Transplantation, Homologous | 4 | 1994 | 6 | 0.030 |
Why?
|
| Antibodies | 2 | 1994 | 25 | 0.030 |
Why?
|
| Professional Staff Committees | 1 | 2016 | 1 | 0.030 |
Why?
|
| Social Welfare | 1 | 2016 | 3 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1994 | 7 | 0.030 |
Why?
|
| United Nations | 1 | 2016 | 12 | 0.030 |
Why?
|
| Sex Offenses | 1 | 2016 | 29 | 0.030 |
Why?
|
| Cholera Toxin | 1 | 1996 | 1 | 0.030 |
Why?
|
| Colforsin | 1 | 1996 | 1 | 0.030 |
Why?
|
| Ionomycin | 1 | 1996 | 1 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1996 | 2 | 0.030 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1996 | 3 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1996 | 3 | 0.030 |
Why?
|
| Zoonoses | 1 | 1996 | 4 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1996 | 7 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1996 | 6 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2016 | 54 | 0.030 |
Why?
|
| Viruses | 1 | 1996 | 47 | 0.030 |
Why?
|
| Killer Cells, Natural | 3 | 1994 | 52 | 0.030 |
Why?
|
| Rural Health | 2 | 2007 | 118 | 0.030 |
Why?
|
| Isoantibodies | 2 | 1994 | 15 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2009 | 480 | 0.030 |
Why?
|
| Marital Status | 2 | 2005 | 11 | 0.030 |
Why?
|
| Learning Curve | 1 | 2014 | 2 | 0.030 |
Why?
|
| Employment | 2 | 2005 | 27 | 0.030 |
Why?
|
| Isoantigens | 1 | 1994 | 2 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1994 | 4 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1991 | 11 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 1991 | 16 | 0.030 |
Why?
|
| Antigens, Heterophile | 1 | 1994 | 2 | 0.030 |
Why?
|
| Uveitis | 1 | 1974 | 5 | 0.030 |
Why?
|
| Behavior, Addictive | 1 | 2014 | 2 | 0.030 |
Why?
|
| Benzamides | 1 | 1994 | 1 | 0.030 |
Why?
|
| Cytarabine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Novobiocin | 1 | 1994 | 1 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1994 | 1 | 0.030 |
Why?
|
| Vidarabine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Aphidicolin | 1 | 1994 | 1 | 0.030 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1994 | 36 | 0.030 |
Why?
|
| Doxorubicin | 1 | 1994 | 8 | 0.030 |
Why?
|
| Gamma Rays | 1 | 1994 | 3 | 0.030 |
Why?
|
| Naphthoquinones | 1 | 1994 | 3 | 0.030 |
Why?
|
| Flavonoids | 1 | 1994 | 7 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 63 | 0.030 |
Why?
|
| Kinetics | 1 | 1994 | 65 | 0.030 |
Why?
|
| Rats | 1 | 1994 | 130 | 0.030 |
Why?
|
| HLA Antigens | 3 | 1991 | 50 | 0.030 |
Why?
|
| Refusal to Treat | 1 | 2013 | 3 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 87 | 0.030 |
Why?
|
| Transgender Persons | 1 | 2013 | 24 | 0.030 |
Why?
|
| Teaching Materials | 1 | 2012 | 2 | 0.030 |
Why?
|
| Selection Bias | 1 | 2012 | 4 | 0.030 |
Why?
|
| Government Regulation | 1 | 2012 | 5 | 0.020 |
Why?
|
| Occupational Health | 1 | 2013 | 24 | 0.020 |
Why?
|
| Marketing of Health Services | 1 | 2012 | 2 | 0.020 |
Why?
|
| Research | 1 | 2012 | 65 | 0.020 |
Why?
|
| Social Conditions | 1 | 2012 | 10 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 1 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1992 | 1 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 89 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 1991 | 1 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2012 | 30 | 0.020 |
Why?
|
| Public Opinion | 1 | 2011 | 6 | 0.020 |
Why?
|
| Immunization | 1 | 1992 | 63 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 43 | 0.020 |
Why?
|
| Madagascar | 1 | 2011 | 3 | 0.020 |
Why?
|
| Lymphatic Irradiation | 1 | 1991 | 2 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 57 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 2 | 0.020 |
Why?
|
| Bone Resorption | 1 | 2010 | 3 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1989 | 3 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 656 | 0.020 |
Why?
|
| Social Control, Informal | 1 | 2009 | 5 | 0.020 |
Why?
|
| Time | 1 | 2009 | 3 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 111 | 0.020 |
Why?
|
| Role | 1 | 2009 | 4 | 0.020 |
Why?
|
| Child, Preschool | 2 | 1991 | 1748 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1988 | 60 | 0.020 |
Why?
|
| Medroxyprogesterone | 1 | 2008 | 1 | 0.020 |
Why?
|
| Blood | 1 | 1988 | 51 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1987 | 7 | 0.020 |
Why?
|
| Social Class | 1 | 2007 | 73 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 85 | 0.020 |
Why?
|
| Social Conformity | 1 | 2006 | 2 | 0.020 |
Why?
|
| Social Marketing | 1 | 2006 | 3 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2006 | 8 | 0.020 |
Why?
|
| Schools | 1 | 2006 | 73 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1987 | 142 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2004 | 30 | 0.010 |
Why?
|
| Emergencies | 1 | 2004 | 16 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 1991 | 25 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 1983 | 27 | 0.010 |
Why?
|
| Exercise | 1 | 2005 | 205 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1994 | 73 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 1992 | 2 | 0.010 |
Why?
|
| Antibodies, Viral | 2 | 1996 | 284 | 0.010 |
Why?
|
| Liver Transplantation | 2 | 1994 | 55 | 0.010 |
Why?
|
| Cyclosporins | 2 | 1991 | 3 | 0.010 |
Why?
|
| Azathioprine | 2 | 1991 | 4 | 0.010 |
Why?
|
| Prednisone | 2 | 1991 | 17 | 0.010 |
Why?
|
| Transplantation Immunology | 2 | 1987 | 2 | 0.010 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1996 | 2 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 5 | 0.010 |
Why?
|
| Spleen | 1 | 1996 | 9 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1996 | 6 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1996 | 13 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1996 | 27 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 55 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 149 | 0.010 |
Why?
|
| DNA | 1 | 1996 | 73 | 0.010 |
Why?
|
| Kidney | 1 | 1996 | 46 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 263 | 0.010 |
Why?
|
| Virus Replication | 1 | 1996 | 88 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 260 | 0.010 |
Why?
|
| Lens, Crystalline | 1 | 1974 | 1 | 0.010 |
Why?
|
| Scintillation Counting | 1 | 1974 | 1 | 0.010 |
Why?
|
| Tritium | 1 | 1974 | 1 | 0.010 |
Why?
|
| Uvea | 1 | 1974 | 1 | 0.010 |
Why?
|
| Antigens | 1 | 1974 | 11 | 0.010 |
Why?
|
| Thymidine | 1 | 1974 | 6 | 0.010 |
Why?
|
| Species Specificity | 1 | 1994 | 49 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1994 | 35 | 0.010 |
Why?
|
| Solubility | 1 | 1974 | 51 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1994 | 2 | 0.010 |
Why?
|
| Biopsy | 1 | 1994 | 38 | 0.010 |
Why?
|
| Cell Division | 1 | 1994 | 12 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1994 | 30 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1994 | 29 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1994 | 67 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1992 | 5 | 0.010 |
Why?
|
| CD56 Antigen | 1 | 1992 | 5 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1992 | 3 | 0.010 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1991 | 1 | 0.010 |
Why?
|
| Hemagglutination | 1 | 1991 | 3 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1992 | 26 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1991 | 44 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1989 | 149 | 0.000 |
Why?
|
| Radiotherapy Dosage | 1 | 1989 | 13 | 0.000 |
Why?
|
| Reference Values | 1 | 1989 | 64 | 0.000 |
Why?
|
| Cobalt Radioisotopes | 1 | 1987 | 4 | 0.000 |
Why?
|
| Radiation Dosage | 1 | 1986 | 2 | 0.000 |
Why?
|
| Bone Marrow Transplantation | 1 | 1986 | 3 | 0.000 |
Why?
|
| Actuarial Analysis | 1 | 1983 | 1 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1983 | 13 | 0.000 |
Why?
|
| Acute Kidney Injury | 1 | 1983 | 15 | 0.000 |
Why?
|
| Consanguinity | 1 | 1976 | 2 | 0.000 |
Why?
|